Document Detail


Acute venous thromboembolism.
MedLine Citation:
PMID:  16597316     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To review the recent advances in management of acute venous thromboembolism. DATA SOURCES: Articles and published reviews on venous thromboembolism, pulmonary embolism and deep vein thrombosis. SUMMARY OF REVIEW: Acute venous thromboembolism describes a group of disorders that include venous thrombosis (usually deep vein thrombosis) and pulmonary thromboembolism. Ultrasound supplemented by Doppler flow detection imaging has become the investigation of choice in the diagnosis of deep vein thrombosis and spiral volumetric computed tomography or ventilation perfusion scan (if the patient is haemodynamically stable) or bedside echocardiography (if the patient is hypotensive) are often the initial investigations in a patient who has a suspected pulmonary thromboembolism. Magnetic resonance venography has only recently been evaluated and may prove in future to be a valuable diagnostic test for both deep vein thrombosis and pulmonary thromboembolism. Treatment requires immediate anticoagulation using either subcutaneous low molecular weight heparin (e.g. enoxaparin 1 mg/kg 12-hourly or dalteparin 100 IU anti Xa/kg twice daily) or intravenous unfractionated heparin (80 U/kg as a bolus then 18 U/kg/hr and adjusted to keep the APTT 1.5-2x the control value). Oral anticoagulation using warfarin is started simultaneously with heparin. Fibrinolytic therapy is considered in all patients with pulmonary thromboembolism in whom there are no contraindications, as the improvement in right ventricular function is greater and the pulmonary artery perfusion defect is less compared with patients treated by anticoagulation alone. Fibrinolytic therapy is usually only considered in patients with deep vein thrombosis if severe limb oedema is present. While streptokinase, urokinase and alteplase have been recommended, alteplase (100 mg over two hours with heparinisation) may be the treatment of choice as alteplase has a shorter half life, has a more rapid effect and may be more effective in lysing older clots, when compared with streptokinase or urokinase. Reteplase (10 U over 2 minutes followed by 10 U 30 minutes later) may be as effective as alteplase. CONCLUSIONS: Acute venous thromboembolism is a disorder that carries a high morbidity and mortality. Anticoagulation with or without fibrinolysis is the treatment of choice.
Authors:
M C Atkinson; L I Worthley
Related Documents :
17261866 - Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism.
3392086 - Low incidence of deep-vein thrombosis after cementless total hip replacement.
10344506 - Consequences of the anatomy of deep venous outflow from the brain.
12939926 - The best study--a prospective study to compare business class versus economy class air ...
20465936 - Guidewire tip detachment during stent-assisted coiling of an intracranial aneurysm. a c...
494036 - Cirrhosis of the liver associated with inferior vena-caval obstruction.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine     Volume:  2     ISSN:  1441-2772     ISO Abbreviation:  Crit Care Resusc     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2006-04-06     Completed Date:  2006-04-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888170     Medline TA:  Crit Care Resusc     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  290-303     Citation Subset:  -    
Affiliation:
Department of Critical Care Medicine, Flinders Medical Centre, Adelaide, South Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections
Comment In:
Crit Care Resusc. 2000 Dec;2(4):244-5   [PMID:  16597309 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Towards better ICU antibiotic dosing.
Next Document:  Xenopus death-domain-containing proteins FADD and RIP1 synergistically activate JNK and NF-kappaB.